Heparin oral - Guangzhou Dazhou Biomedicine
Alternative Names: SHX-020Latest Information Update: 22 Dec 2022
At a glance
- Originator Guangzhou Dazhou Biomedicine
- Class Anti-infectives; Anti-inflammatories; Antianaemics; Antithrombotics; Bronchodilators; Heparins; Mucolytics
- Mechanism of Action Factor Xa inhibitors; Heparanase inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Sickle cell anaemia; Venous thrombosis
Most Recent Events
- 18 Nov 2022 Preclinical trials in Sickle cell anaemia in US (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)
- 18 Nov 2022 Preclinical trials in Venous thrombosis (Prevention) in USA (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)
- 18 Nov 2022 Preclinical trials in Venous thrombosis in US (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)